Vernalis (R&D) Ltd
13
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
1 terminated/withdrawn out of 13 trials
92.3%
+5.8% vs industry average
15%
2 trials in Phase 3/4
8%
1 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
Role: collaborator
A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine
Role: collaborator
A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury
Role: collaborator
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
Role: lead
Safety and Efficacy Study in Acute Ischaemic Stroke
Role: lead
Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain
Role: lead
A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease
Role: lead
Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers
Role: lead
A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men
Role: lead
Phase II Open-Label Pilot Study of V3381 in Chronic Cough
Role: lead
Safety and Efficacy of Low Doses of V24343 in Obese Subjects
Role: lead
PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
Role: lead
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
Role: lead
All 13 trials loaded